Carregant...
Progress and challenges for treating Type 1 diabetes
It has been more than 30 years since the initial trials of Cyclosporin A to treat patients with new onset Type 1 diabetes (T1D). Since that time, there have been insights into genetic predisposition to the disease, the failures of immune tolerance, and mechanisms that cause the immune mediated β cel...
Guardat en:
| Publicat a: | J Autoimmun |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4903889/ https://ncbi.nlm.nih.gov/pubmed/27210268 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaut.2016.04.004 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|